JP5936821B2 - チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 - Google Patents

チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 Download PDF

Info

Publication number
JP5936821B2
JP5936821B2 JP2010544393A JP2010544393A JP5936821B2 JP 5936821 B2 JP5936821 B2 JP 5936821B2 JP 2010544393 A JP2010544393 A JP 2010544393A JP 2010544393 A JP2010544393 A JP 2010544393A JP 5936821 B2 JP5936821 B2 JP 5936821B2
Authority
JP
Japan
Prior art keywords
imatinib
kit
patient
treatment
cmin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010544393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510086A (ja
JP2011510086A5 (enExample
Inventor
ワン，ヤンフェン
ウェラ，エリザベス
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5936821(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2011510086A publication Critical patent/JP2011510086A/ja
Publication of JP2011510086A5 publication Critical patent/JP2011510086A5/ja
Application granted granted Critical
Publication of JP5936821B2 publication Critical patent/JP5936821B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010544393A 2008-01-23 2009-01-21 チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 Expired - Fee Related JP5936821B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23
US61/022,945 2008-01-23
PCT/US2009/031510 WO2009094360A1 (en) 2008-01-23 2009-01-21 Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013261728A Division JP5881671B2 (ja) 2008-01-23 2013-12-18 チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法

Publications (3)

Publication Number Publication Date
JP2011510086A JP2011510086A (ja) 2011-03-31
JP2011510086A5 JP2011510086A5 (enExample) 2013-05-09
JP5936821B2 true JP5936821B2 (ja) 2016-06-22

Family

ID=40435094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010544393A Expired - Fee Related JP5936821B2 (ja) 2008-01-23 2009-01-21 チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法
JP2013261728A Expired - Fee Related JP5881671B2 (ja) 2008-01-23 2013-12-18 チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013261728A Expired - Fee Related JP5881671B2 (ja) 2008-01-23 2013-12-18 チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法

Country Status (14)

Country Link
US (3) US20100298338A1 (enExample)
EP (1) EP2237783B1 (enExample)
JP (2) JP5936821B2 (enExample)
KR (1) KR101579993B1 (enExample)
CN (1) CN101951910B (enExample)
AU (1) AU2009206566A1 (enExample)
BR (1) BRPI0906504A2 (enExample)
CA (1) CA2712087A1 (enExample)
ES (1) ES2526537T3 (enExample)
MX (1) MX2010008103A (enExample)
PL (1) PL2237783T3 (enExample)
PT (1) PT2237783E (enExample)
RU (1) RU2537223C2 (enExample)
WO (1) WO2009094360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
SI1686997T1 (sl) * 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
EP2251042A3 (en) * 2006-09-22 2012-05-02 Novartis AG Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
CA2668828A1 (en) 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate

Also Published As

Publication number Publication date
EP2237783B1 (en) 2014-11-19
PT2237783E (pt) 2014-12-23
PL2237783T3 (pl) 2015-04-30
AU2009206566A1 (en) 2009-07-30
CA2712087A1 (en) 2009-07-30
US20170035757A1 (en) 2017-02-09
CN101951910A (zh) 2011-01-19
WO2009094360A1 (en) 2009-07-30
JP2011510086A (ja) 2011-03-31
JP2014094946A (ja) 2014-05-22
RU2537223C2 (ru) 2014-12-27
US9763944B2 (en) 2017-09-19
RU2010134916A (ru) 2012-02-27
ES2526537T3 (es) 2015-01-13
EP2237783A1 (en) 2010-10-13
JP5881671B2 (ja) 2016-03-09
US20100298338A1 (en) 2010-11-25
KR20100105778A (ko) 2010-09-29
CN101951910B (zh) 2013-07-17
KR101579993B1 (ko) 2015-12-23
MX2010008103A (es) 2010-08-23
US20160045501A1 (en) 2016-02-18
BRPI0906504A2 (pt) 2015-07-14

Similar Documents

Publication Publication Date Title
US20220152026A1 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
CN102647986A (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
JP2021522246A (ja) 癌治療のための併用
TW202140015A (zh) 用於治療癌症之表皮生長因子受體酪胺酸激酶抑制劑
JP5936821B2 (ja) チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
CN114430681A (zh) 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症
MX2008001971A (es) Combinacion de compuestos organicos.
JP2011510086A5 (enExample)
JP2007507552A (ja) Ｉｇｆ１ｒ阻害剤が誘発する高血糖を治療する方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130918

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140616

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140729

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160511

R150 Certificate of patent or registration of utility model

Ref document number: 5936821

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees